Ambu Q1 2019/20 Investor Presentation Results

Ambu reports strong Q1 2019/20 results with 14% organic growth driven by visualization products and completed US aScope distributor transition. The company is launching three key single-use endoscopy products (Cystoscope, aView 2 Advance, Duodenoscope) and expanding commercial operations across geographies.